Trial Profile
A Retrospective Study of Omalizumab treated with Chronic Spontaneous Urticaria
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2018
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 08 May 2018 New trial record